CoLucid pockets $4M for PhIII migraine drug trial

CoLucid Pharmaceuticals has injected some capital into its R&D tank with a $4 million funding tranche. The company has plans to drive toward a Phase III trial of lasmiditan, its lead drug for treating migraines, late next year, the Triangle Business Journal reports. The Durham, NC-based developer tapped Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures for the financing. Report